{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:26:00Z","timestamp":1784031960364,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Diffuse midline glioma (DMG), H3 K27M-mutant is a type of diffuse high-grade glioma that occurs in the brain midline carrying an extremely poor prognosis under the best efforts of surgery, radiation, and other therapies. For better therapy, we explored the efficacy and toxicity of a novel therapy that combines apatinib and temozolomide in DMG.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective analysis of 32 patients with DMG who underwent apatinib plus temozolomide treatment was performed. Apatinib was given 500\u00a0mg in adults, 250\u00a0mg in pediatric patients once daily. Temozolomide was administered at 200\u00a0mg\/m<jats:sup>2<\/jats:sup>\/d according to the standard 5\/28\u00a0days regimen. The main clinical data included basic information of patients, radiological and pathological characteristics of tumors, treatment, adverse reactions, prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The objective response rate was 24.1%, and the disease control rate was 79.3%. The median PFS of all patients was 5.8\u00a0months, and median OS was 10.3\u00a0months. A total of 236 cycles of treatment were available for safety assessment and the toxicity of the combination therapy was relatively well tolerated. The most common grade 3 toxicities were myelosuppression including leukopenia (5.08%), neutropenia (4.24%), lymphopenia (2.12%), thrombocytopenia (1.69%) and anemia (1.27%). Grade 4 toxicities included neutropenia (2.12%), thrombocytopenia (2.12%) and proteinuria (1.69%). All the adverse events were relieved after symptomatic treatment or dose reduction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Apatinib plus temozolomide could be an effective regimen with manageable toxicities and favorable efficacy and may outperform temozolomide monotherapy, particularly in newly diagnosed adults with tumors located outside the pons. The novel therapy deserves further investigation in adult DMG patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-024-12373-9","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T13:02:15Z","timestamp":1718974935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Apatinib combined with temozolomide in diffuse midline glioma: a novel and effective therapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Yu-An","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Jing","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Jun","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Pei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Chen","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"issue":"6","key":"12373_CR1","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803\u201320.","journal-title":"Acta Neuropathol"},{"issue":"8","key":"12373_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231\u201351.","journal-title":"Neuro Oncol"},{"issue":"8","key":"12373_CR3","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1093\/neuonc\/nox021","volume":"19","author":"KJ Cohen","year":"2017","unstructured":"Cohen KJ, Jabado N, Grill J. Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope? Neuro Oncol. 2017;19(8):1025\u201334.","journal-title":"Neuro Oncol"},{"issue":"4","key":"12373_CR4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s10555-019-09824-2","volume":"38","author":"WM Rashed","year":"2019","unstructured":"Rashed WM, Maher E, Adel M, Saber O, Zaghloul MS. Pediatric diffuse intrinsic pontine glioma: where do we stand? Cancer Metastasis Rev. 2019;38(4):759\u201370.","journal-title":"Cancer Metastasis Rev"},{"issue":"6","key":"12373_CR5","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1097\/PAS.0000000000001897","volume":"46","author":"L Zheng","year":"2022","unstructured":"Zheng L, Gong J, Yu T, Zou Y, Zhang M, Nie L, Chen X, Yue Q, Liu Y, Mao Q, et al. Diffuse midline gliomas with histone H3 K27M mutation in adults and children: a retrospective series of 164 cases. Am J Surg Pathol. 2022;46(6):863\u201371.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"12373_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/neuonc\/noq202","volume":"13","author":"DA Haas-Kogan","year":"2011","unstructured":"Haas-Kogan DA, Banerjee A, Poussaint TY, Kocak M, Prados MD, Geyer JR, Fouladi M, Broniscer A, Minturn JE, Pollack IF, et al. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol. 2011;13(3):298\u2013306.","journal-title":"Neuro Oncol"},{"issue":"12","key":"12373_CR7","first-page":"1339","volume":"20","author":"A Gajjar","year":"2022","unstructured":"Gajjar A, Mahajan A, Abdelbaki M, Anderson C, Antony R, Bale T, Bindra R, Bowers DC, Cohen K, Cole B, et al. Pediatric central nervous system cancers, version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(12):1339\u201362.","journal-title":"J Natl Compr Canc Netw"},{"key":"12373_CR8","first-page":"209","volume":"94","author":"N Ferrara","year":"2005","unstructured":"Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS. 2005;94:209\u201331.","journal-title":"EXS"},{"issue":"5","key":"12373_CR9","first-page":"5607","volume":"16","author":"C Wang","year":"2018","unstructured":"Wang C, Jiang M, Hou H, Lin Q, Yan Z, Zhang X. Apatinib suppresses cell growth and metastasis and promotes antitumor activity of temozolomide in glioma. Oncol Lett. 2018;16(5):5607\u201314.","journal-title":"Oncol Lett"},{"issue":"13","key":"12373_CR10","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","volume":"34","author":"J Li","year":"2016","unstructured":"Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34(13):1448\u201354.","journal-title":"J Clin Oncol"},{"issue":"9","key":"12373_CR11","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(18)30349-8","volume":"19","author":"CY Lan","year":"2018","unstructured":"Lan CY, Wang Y, Xiong Y, Li JD, Shen JX, Li YF, Zheng M, Zhang YN, Feng YL, Liu Q, et al. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study. Lancet Oncol. 2018;19(9):1239\u201346.","journal-title":"Lancet Oncol"},{"issue":"6","key":"12373_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/15384047.2017.1323589","volume":"18","author":"W Lu","year":"2017","unstructured":"Lu W, Jin XL, Yang C, Du P, Jiang FQ, Ma JP, Yang J, Xie P, Zhang Z. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: a single-center randomized controlled trial. Cancer Biol Ther. 2017;18(6):433\u20138.","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"12373_CR13","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/ajco.12870","volume":"14","author":"D Wu","year":"2018","unstructured":"Wu D, Liang L, Nie L, Nie J, Dai L, Hu W, Zhang J, Chen X, Han J, Ma X, et al. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: apatinib treatment in nonsquamous NSCLC. Asia Pac J Clin Oncol. 2018;14(6):446\u201352.","journal-title":"Asia Pac J Clin Oncol"},{"key":"12373_CR14","doi-asserted-by":"publisher","first-page":"601175","DOI":"10.3389\/fonc.2020.601175","volume":"10","author":"J Ge","year":"2020","unstructured":"Ge J, Li C, Xue F, Qi S, Gao Z, Yu C, Zhang J. Apatinib plus temozolomide: an effective salvage treatment for recurrent glioblastoma. Front Oncol. 2020;10:601175.","journal-title":"Front Oncol"},{"key":"12373_CR15","doi-asserted-by":"publisher","first-page":"6539","DOI":"10.2147\/OTT.S176429","volume":"11","author":"D Sun","year":"2018","unstructured":"Sun D, Hou H, Zhang C, Zhang X. The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis. Onco Targets Ther. 2018;11:6539\u201354.","journal-title":"Onco Targets Ther"},{"key":"12373_CR16","doi-asserted-by":"publisher","first-page":"10579","DOI":"10.2147\/OTT.S226804","volume":"12","author":"Y Wang","year":"2019","unstructured":"Wang Y, Meng X, Zhou S, Zhu Y, Xu J, Tao R. Apatinib plus temozolomide for recurrent glioblastoma: an uncontrolled\u00a0open-label study. Onco Targets Ther. 2019;12:10579\u201385.","journal-title":"Onco Targets Ther"},{"key":"12373_CR17","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.2147\/OTT.S195783","volume":"12","author":"D Yu","year":"2019","unstructured":"Yu D, Han G, Liu H, Gao L, Verma V. Treatment of adult brainstem glioma with combined antiangiogenic therapy: a case report and literature review. Onco Targets Ther. 2019;12:1333\u20139.","journal-title":"Onco Targets Ther"},{"issue":"5","key":"12373_CR18","first-page":"2579","volume":"24","author":"Y Luo","year":"2020","unstructured":"Luo Y, Zeng L, Xie XQ, Wang F, Liu YZ, Kang JB, Li XF, Wu DB, Qu BL. H3K27M mutant diffuse midline glioma: a case report. Eur Rev Med Pharmacol Sci. 2020;24(5):2579\u201384.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"12373_CR19","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S1470-2045(20)30173-X","volume":"21","author":"C Erker","year":"2020","unstructured":"Erker C, Tamrazi B, Poussaint T, Mueller S, Mata-Mbemba D, Franceschi E, Brandes A, Rao A, Haworth K, Wen P, et al. Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol. 2020;21(6):e317\u201329.","journal-title":"Lancet Oncol"},{"issue":"1","key":"12373_CR20","first-page":"vdaa142","volume":"2","author":"JD Schulte","year":"2020","unstructured":"Schulte JD, Buerki RA, Lapointe S, Molinaro AM, Zhang Y, Villanueva-Meyer JE, Perry A, Phillips JJ, Tihan T, Bollen AW, et al. Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. Neurooncol Adv. 2020;2(1):vdaa142.","journal-title":"Neurooncol Adv"},{"issue":"4","key":"12373_CR21","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/neuonc\/noq205","volume":"13","author":"KJ Cohen","year":"2011","unstructured":"Cohen KJ, Heideman RL, Zhou T, Holmes EJ, Lavey RS, Bouffet E, Pollack IF. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children\u2019s Oncology Group. Neuro Oncol. 2011;13(4):410\u20136.","journal-title":"Neuro Oncol"},{"issue":"18","key":"12373_CR22","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1016\/j.ejca.2013.08.006","volume":"49","author":"S Bailey","year":"2013","unstructured":"Bailey S, Howman A, Wheatley K, Wherton D, Boota N, Pizer B, Fisher D, Kearns P, Picton S, Saran F, et al. Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy\u2013results of a United Kingdom phase II trial (CNS 2007 04). Eur J Cancer. 2013;49(18):3856\u201362.","journal-title":"Eur J Cancer"},{"issue":"1","key":"12373_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/neuonc\/not144","volume":"16","author":"K Aihara","year":"2014","unstructured":"Aihara K, Mukasa A, Gotoh K, Saito K, Nagae G, Tsuji S, Tatsuno K, Yamamoto S, Takayanagi S, Narita Y, et al. H3F3A K27M mutations in thalamic gliomas from young adult patients. Neuro Oncol. 2014;16(1):140\u20136.","journal-title":"Neuro Oncol"},{"issue":"4","key":"12373_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.14791\/btrt.2022.0035","volume":"10","author":"SW Jang","year":"2022","unstructured":"Jang SW, Song SW, Kim YH, Cho YH, Hong SH, Kim JH, Ra YS, Chong S. Clinical features and prognosis of diffuse midline glioma: a series of 24 cases. Brain Tumor Res Treat. 2022;10(4):255\u201364.","journal-title":"Brain Tumor Res Treat"},{"issue":"11","key":"12373_CR25","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1158\/2159-8290.CD-23-0131","volume":"13","author":"S Venneti","year":"2023","unstructured":"Venneti S, Kawakibi A, Ji S, Waszak S, Sweha S, Mota M, Pun M, Deogharkar A, Chung C, Tarapore R, et al. Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways. Cancer Discov. 2023;13(11):2370\u201393.","journal-title":"Cancer Discov"},{"issue":"6","key":"12373_CR26","doi-asserted-by":"publisher","first-page":"e26988","DOI":"10.1002\/pbc.26988","volume":"65","author":"A Lassaletta","year":"2018","unstructured":"Lassaletta A, Strother D, Laperriere N, Hukin J, Vanan MI, Goddard K, Lafay-Cousin L, Johnston DL, Zelcer S, Zapotocky M, et al. Reirradiation in patients with diffuse intrinsic pontine gliomas: the Canadian experience. Pediatr Blood Cancer. 2018;65(6):e26988.","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"12373_CR27","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/neuonc\/nou091","volume":"16","author":"U Bartels","year":"2014","unstructured":"Bartels U, Wolff J, Gore L, Dunkel I, Gilheeney S, Allen J, Goldman S, Yalon M, Packer RJ, Korones DN, et al. Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. Neuro Oncol. 2014;16(11):1554\u20139.","journal-title":"Neuro Oncol"},{"issue":"7","key":"12373_CR28","doi-asserted-by":"publisher","first-page":"e27035","DOI":"10.1002\/pbc.27035","volume":"65","author":"A Broniscer","year":"2018","unstructured":"Broniscer A, Jia S, Mandrell B, Hamideh D, Huang J, Onar-Thomas A, Gajjar A, Raimondi SC, Tatevossian RG, Stewart CF. Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma. Pediatr Blood Cancer. 2018;65(7):e27035.","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"12373_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11060-021-03763-1","volume":"153","author":"FE El-Khouly","year":"2021","unstructured":"El-Khouly FE, Veldhuijzen van Zanten SEM, Jansen MHA, Bakker DP, Sanchez Aliaga E, Hendrikse NH, Vandertop WP, van Vuurden DG, Kaspers GJL. A phase I\/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma. J Neurooncol. 2021;153(2):263\u201371.","journal-title":"J Neurooncol"}],"updated-by":[{"DOI":"10.1186\/s12885-024-12600-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000}}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12373-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12373-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12373-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T13:02:45Z","timestamp":1720702965000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12373-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12373"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12373-9","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12885-024-12600-3","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]},"assertion":[{"value":"20 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12885-024-12600-3","URL":"https:\/\/doi.org\/10.1186\/s12885-024-12600-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was reviewed and approved by the human subjects\u2019 institutional review boards of Sanbo Brain Hospital of Capital Medical University. Written informed consent was obtained from the families of all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declared no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"754"}}